Latest & greatest articles for aspirin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aspirin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aspirin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Aspirin

Acetylsalicylic acid (ASA) more commonly known as aspirin is a painkiller that has a wide range of uses. It is frequently used to treat fever, mild pain, tooth aches, headaches and muscle aches. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and can be used in the management of conditions such as heart attack, arthritis, blood clots and stroke. Aspirin, has been used for thousands of years, initially extracted from the leaves of willow trees.

Aspirin works in much the same way as other NSAIDs but has additional properties, such as antiplatelet activity which can make it additionally useful. More recently aspirin has been linked with cancer prevention. But the potential benefits of aspirin need to be weighed against the potential side effects, which includes gastrointestinal bleeding and Reye’s syndrome. It should be noted that aspirin should not be used in people who are allergic to drugs such as ibuprofen or a more generalized intolerance to NSAIDs. It should also be used cautiously in asthmatics and/or those with bronchospasm associated with NSAID use.

Research evidence, clinical trials and guidelines on Aspirin

The Trip Database has an extensive collection of articles on aspirin ranging from clinical trials, systematic reviews, clinical guidelines and case reports. These can be found via searching the site.

Top results for aspirin

381. Prevention of preeclampsia with low-dose aspirin: a systematic review and meta-analysis of the main randomized controlled trials

Prevention of preeclampsia with low-dose aspirin: a systematic review and meta-analysis of the main randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

382. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone

A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone Schleinitz M D, Heidenreich P A Record (...) (75 mg/day) plus aspirin (325 mg/day). Type of intervention Secondary prevention. Economic study type Cost-utility analysis. Study population The study population comprised a hypothetical cohort of patients with unstable angina or non-Q wave MI. The patients included in the analysis were suffering from an ACS characterised by electrocardiographic changes or elevated serum cardiac markers in association with chest pain. Patients who had prolonged ST-segment elevation, or who had undergone

2005 NHS Economic Evaluation Database.

383. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden

The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden Lindgren P, Stenestrand U, Malmberg K, Jonsson B Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined percutaneous coronary intervention (PCI) with clopidogrel plus aspirin versus aspirin alone in patients with unstable coronary artery disease (CAD). Type of intervention Treatment. Economic study type Cost-effectiveness

2005 NHS Economic Evaluation Database.

384. Analysis of aspirin-associated risks in healthy individuals

Analysis of aspirin-associated risks in healthy individuals Analysis of aspirin-associated risks in healthy individuals Analysis of aspirin-associated risks in healthy individuals Hur C, Simon L S, Gazelle G S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) and the conclusions drawn. Health technology The study examined the use aspirin 325 mg daily in healthy individuals. Type of intervention Primary prevention. Economic study type Cost-utility analysis. Study population The study population comprised a hypothetical cohort of healthy individuals of 50 years of age. Setting The setting was primary care. The economic study was carried out in the USA. Dates to which data relate The effectiveness data and some resource use data were derived from studies published

2005 NHS Economic Evaluation Database.

385. Aspirin sensitivity: implications for patients with coronary artery disease. Full Text available with Trip Pro

Aspirin sensitivity: implications for patients with coronary artery disease. Although acetylsalicylic acid (aspirin) is commonly used for patients with chronic cardiovascular disease, a minority of patients have a sensitivity to acetylsalicylic acid and other nonsteroidal anti-inflammatory drugs.To provide a diagnostic strategy for evaluating and treating patients with aspirin sensitivity, with additional consideration for issues specific to patients with coronary artery disease (CAD).Published (...) with acetylsalicylic acid sensitivity are able to undergo desensitization therapy safely and successfully except in cases of chronic idiopathic urticaria. However, there have not been any randomized trials that specifically focus on the efficacy of aspirin desensitization. Furthermore, experience with acetylsalicylic acid desensitization in patients with CAD is very limited. After successful desensitization, acetylsalicylic acid therapy must be indefinitely continued to prevent resensitization.Acetylsalicylic acid

2004 JAMA

386. Aspirin prevented new colorectal adenomas in patients with previous colorectal cancer Full Text available with Trip Pro

Aspirin prevented new colorectal adenomas in patients with previous colorectal cancer Aspirin prevented new colorectal adenomas in patients with previous colorectal cancer | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Aspirin prevented new colorectal adenomas in patients with previous colorectal cancer Article Text Therapeutics Aspirin prevented new colorectal adenomas in patients with previous colorectal cancer Free James E Shaw

2004 Evidence-Based Medicine

387. Chemoprophylaxis with aspirin (81 mg daily) reduced the incidence of colorectal adenomas in people at risk Full Text available with Trip Pro

Chemoprophylaxis with aspirin (81 mg daily) reduced the incidence of colorectal adenomas in people at risk Chemoprophylaxis with aspirin (81 mg daily) reduced the incidence of colorectal adenomas in people at risk | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Chemoprophylaxis with aspirin (81 mg daily) reduced the incidence of colorectal adenomas in people at risk Article Text Therapeutics Chemoprophylaxis with aspirin (81 mg daily

2004 Evidence-Based Medicine

388. Gastric lavage in aspirin and non-steroidal anti-inflammatory drug overdose

Altogether 72 papers found 71 of which failed to answer the three part question. A further reference was found after scanning of references. The 2 papers are shown below. Relevant Paper(s) Author, date and country Patient group Study type (level of evidence) Outcomes Key results Study Weaknesses Danel V et al, 1988, UK 12 healthy volunteers given 1.5g aspirin acting as own controls treated with nothing, charcoal and lavage Prospective controlled study Salicylate recovered in urine over 24h Control 13.3 (...) Gastric lavage in aspirin and non-steroidal anti-inflammatory drug overdose BestBets: Gastric lavage in aspirin and non-steroidal anti-inflammatory drug overdose Gastric lavage in aspirin and non-steroidal anti-inflammatory drug overdose Report By: Stewart Teece - Clinical Research Fellow Search checked by Ian Crawford - Clinical Research Fellow Institution: Manchester Royal Infirmary Current web editor: Simon Carley - Consultant in Emergency Medicine Date Submitted: 1st March 2000 Date

2004 BestBETS

389. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. (Abstract)

Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Clopidogrel was superior to aspirin in patients with previous manifestations of atherothrombotic disease in the CAPRIE study and its benefit was amplified in some high-risk subgroups of patients. We aimed to assess whether addition of aspirin to clopidogrel could have a greater benefit than (...) clopidogrel alone in prevention of vascular events with potentially higher bleeding risk.We did a randomised, double-blind, placebo-controlled trial to compare aspirin (75 mg/day) with placebo in 7599 high-risk patients with recent ischaemic stroke or transient ischaemic attack and at least one additional vascular risk factor who were already receiving clopidogrel 75 mg/day. Duration of treatment and follow-up was 18 months. The primary endpoint was a composite of ischaemic stroke, myocardial infarction

2004 Lancet Controlled trial quality: predicted high

390. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. Full Text available with Trip Pro

Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. Use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) has been associated with a decrease in the risk of several cancers, including breast cancer. NSAIDs inhibit cyclooxygenase activity and thereby reduce prostaglandin synthesis; prostaglandins stimulate aromatase gene expression and thereby stimulate estrogen biosynthesis. Given the importance of estrogen (...) in the pathogenesis of breast cancer, the ability of aspirin and other NSAIDs to protect against breast cancer could vary according to hormone receptor status.To determine the association between the frequency and duration of use of aspirin and other NSAIDs and breast cancer risk and to investigate whether any observed association is more pronounced for women with hormone receptor-positive breast cancers.Population-based case-control study of women with breast cancer, including in-person interviews conducted

2004 JAMA

391. A prospective study of aspirin use and the risk for colorectal adenoma. (Abstract)

A prospective study of aspirin use and the risk for colorectal adenoma. Randomized, double-blind, placebo-controlled trials have established that regular aspirin use reduces the risk for recurrent colorectal adenoma. However, the effect of dose and duration of use, particularly in an average-risk population, is not well understood.To examine the influence of dose and duration of aspirin use in the primary prevention of colorectal adenoma.Prospective cohort study.Nurses' Health Study.27 077 (...) women, 34 to 77 years of age, without a history of adenoma, cancer, inflammatory bowel disease, or familial polyposis, who underwent lower endoscopy between 1980 and 1998.1368 cases of confirmed distal colorectal adenoma were diagnosed between 1980 and 1998. Self-reported data on aspirin use were collected from biennial questionnaires.After other risk factors for adenoma were adjusted, women who regularly used aspirin (> or =2 standard aspirin tablets/wk) had a multivariate relative risk for adenoma

2004 Annals of Internal Medicine

392. Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas. (Abstract)

for the prevention or regression of CRAs and CRC.Randomized controlled trials (RCTs) up to September 2003 were identified.NSAIDS and aspirin (ASA) were the interventions. The primary outcomes were the number of subjects with at least one CRA, the change in polyp burden, and CRC. The secondary outcome was adverse events.Two reviewers independently extracted data and assessed trial quality. Dichotomous outcomes were reported as relative risks (RR) with 95% confidence intervals (CI). The data were combined (...) with the random effects model if clinically and statistically reasonable.Nine trials with 150 familial adenomatous polyposis (FAP) and 24,143 population subjects met the inclusion criteria. The interventions included sulindac, celecoxib, or aspirin (ASA). From the combined results of three trials, significantly fewer subjects in the low dose ASA group developed recurrent sporadic CRAs [RR 0.77 (95% CI 0.61, 0.96), (NNT 12.5 (95% CI 7.7, 25)] after one to three years. In another three trials, phenotypic FAP

2004 Cochrane

393. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation

Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute (...) coronary syndromes: a systematic review and economic evaluation Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, et al Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, et al. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST

2004 Health Technology Assessment (HTA) Database.

394. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. Full Text available with Trip Pro

Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. Enoxaparin or the combination of glycoprotein IIb/IIIa inhibitor tirofiban with unfractionated heparin independently have shown superior efficacy over unfractionated heparin alone in patients with non-ST-elevation acute coronary syndromes (ACS). It is not clear if combining enoxaparin with glycoprotein (...) heparin (n = 1961) in patients with non-ST-elevation ACS receiving tirofiban and aspirin. Phase A of the A to Z trial was conducted between December 1999 and May 2002.Death, recurrent myocardial infarction, or refractory ischemia at 7 days in the intent-to-treat population with boundaries set for superiority and noninferiority. Safety based on measures of bleeding using the Thrombolysis in Myocardial Infarction (TIMI) classification system.A total of 169 (8.4%) of 2018 patients randomized

2004 JAMA Controlled trial quality: predicted high

395. Efficacy and safety of low-dose aspirin in polycythemia vera. Full Text available with Trip Pro

Efficacy and safety of low-dose aspirin in polycythemia vera. The use of aspirin for the prevention of thrombotic complications in polycythemia vera is controversial.We enrolled 518 patients with polycythemia vera, no clear indication for aspirin treatment, and no contraindication to such treatment in a double-blind, placebo-controlled, randomized trial to assess the safety and efficacy of prophylaxis with low-dose aspirin (100 mg daily). The two primary end points were the cumulative rate (...) of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes and the cumulative rate of nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thrombosis, or death from cardiovascular causes. The mean duration of follow-up was about three years.Treatment with aspirin, as compared with placebo, reduced the risk of the combined end point of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes (relative risk, 0.41; 95

2004 NEJM Controlled trial quality: predicted high

396. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation

Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute (...) coronary syndromes: a systematic review and economic evaluation Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, Henderson R, Sudlow C, Hawkins N, Riemsma R CRD summary This review found that clopidogrel in combination with standard therapy was significantly more effective than aspirin alone for the treatment of acute coronary syndromes. Overall, this was a well-conducted review and the authors' conclusions are supported by the evidence presented. Authors' objectives To review the clinical

2004 DARE.

397. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice

Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 DARE.

398. Systematic review of efficacy of topical rubefacients containing salicylates for the treatment of acute and chronic pain

Systematic review of efficacy of topical rubefacients containing salicylates for the treatment of acute and chronic pain Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 DARE.

399. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis

Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis Schleinitz M D, Weiss J P, Owens D K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two alternative antiplatelet therapies, aspirin (325 mg orally per day) and clopidogrel (75 mg orally per day), were examined. Type of intervention Secondary prevention. Economic study type Cost-utility analysis. Study population The study population comprised a hypothetical cohort of patients with peripheral arterial disease, a non

2004 NHS Economic Evaluation Database.

400. Economic assessment of the secondary prevention of ischaemic stroke with dipyridamole plus aspirin (Aggrenox/Asasantin) in France

of stroke or transient ischemic attack. Arch Intern Med 2000;160:2773-8. Marissal JP, Selke B, Lebrun T. Economic assessment of the secondary prevention of ischaemic events with lysine acetylsalicylate. Pharmacoeconomics 2000;18:185-200. Indexing Status Subject indexing assigned by NLM MeSH Adolescent; Adult; Aged; Aspirin /administration & Aspirin, Dipyridamole Drug Combination; Confidence Intervals; Cost-Benefit Analysis; Dipyridamole /administration & Double-Blind Method; Drug Combinations; Female (...) Economic assessment of the secondary prevention of ischaemic stroke with dipyridamole plus aspirin (Aggrenox/Asasantin) in France Economic assessment of the secondary prevention of ischaemic stroke with dipyridamole plus aspirin (Aggrenox/Asasantin) in France Economic assessment of the secondary prevention of ischaemic stroke with dipyridamole plus aspirin (Aggrenox/Asasantin) in France Marissal J P, Selke B, Amarenco P Record Status This is a critical abstract of an economic evaluation

2004 NHS Economic Evaluation Database.